Call us : 1800 103 7100
Mail us : info@mohanfoundation.org
MOHAN Foundation

Menu

Skip to content
  • About
  • Free Downloads
  • Videos

Can next-generation antibodies offset biosimilar competition? – Nature.com

June 1, 2012Monoclonal Anti-CD20 Antibodiesadmin

Can next-generation antibodies offset biosimilar competition?
Nature.com
Pfizer, more recently, has joined Teva, Novartis, Merck & Co. and others in disclosing that it is testing a biosimilar version of Roche's blockbuster anti-CD20 mAb rituximab in patients. So although there is no stark mAb patent cliff looming on the ...

Post navigation

← Mike Tindall's future may hang on new Gloucester Rugby coach – This is Gloucestershire Heart transplant recipient Erik Compton 1 stroke back at Memorial →

Categories

  • Antibodies
  • Blood donation
  • Bone marrow donation and transplantation
  • Brain Death Declaration
  • Chronic Allograft Nephropathy
  • Donor Card
  • Drugs/Medicine
  • Google News RSS feed URL deprecation
  • Heart
  • HLA Typing
  • Immunosuppressive Drugs
  • Infectious Disease
  • Intestinal
  • Islet
  • Kidney
  • Liver
  • Lung
  • Monoclonal Anti-CD20 Antibodies
  • Monoclonal Anti-IL-2Rα Receptor Antibodies
  • Nephrology
  • Organ Donation
  • Organ Donor
  • Organ Failure
  • Organ Preservation Methods
  • Organ Preservation Solution
  • Organs
  • Other Transplantation
  • Pancreas
  • Pharma News
  • Polyclonal Anti-T-Cell Antibodies
  • Tissue Donation
  • Transplant laws
  • Transplant Rejection
  • Transplant Studies
  • Transplant Surgery
  • Transplant Tourism
  • Transplant Trials
  • Transplantation
  • Uncategorized
Copyright © MOHAN Foundation
Hosted and managed by www.medindindia.net